Several other equities analysts have also recently weighed in on MYO. Zacks Investment Research cut Myomo from a hold rating to a sell rating in a report on Wednesday, May 9th. Roth Capital set a $7.00 price objective on Myomo and gave the company a buy rating in a report on Thursday, May 10th.
MYO opened at $1.95 on Tuesday. Myomo has a 1 year low of $1.74 and a 1 year high of $11.40.
Several institutional investors have recently bought and sold shares of MYO. Citadel Advisors LLC raised its holdings in shares of Myomo by 243.9% during the 1st quarter. Citadel Advisors LLC now owns 40,861 shares of the company’s stock worth $121,000 after buying an additional 28,981 shares in the last quarter. A.R.T. Advisors LLC acquired a new position in shares of Myomo during the 1st quarter worth $277,000. Finally, Account Management LLC acquired a new position in shares of Myomo during the 2nd quarter worth $312,000.
Myomo Company Profile
Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.
Featured Article: Average Daily Trade Volume – ADTV
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.